Nifty
Sensex
:
:
10210.85
32584.35
-23.60 (-0.23%)
-24.81 (-0.08%)

Pharmaceuticals & Drugs

Rating :
45/99   (View)

BSE: 532523 | NSE: BIOCON

382.05
-3.85 (-1.00%)
18-Oct-2017 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 386.25
  • 386.25
  • 377.70
  • 385.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 793428
  • 3031.29
  • 438.85
  • 268.13

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 22,869.00
  • 43.41
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 24,127.20
  • 0.26%
  • 4.65

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 2.92%
  • 12.53%
  • FII
  • DII
  • Others
  • 1.36%
  • 2.46%
  • 20.06%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Net Sales
933.70
982.40
-4.96%
931.10
978.80
-4.87%
1,037.60
836.40
24.06%
945.80
837.20
12.97%
Expenses
741.60
719.30
3.10%
743.60
765.70
-2.89%
761.50
647.30
17.64%
705.80
639.54
10.36%
EBITDA
192.10
263.10
-26.99%
187.50
213.10
-12.01%
276.10
189.10
46.01%
240.00
197.66
21.42%
EBIDTM
20.57%
26.78%
20.14%
21.77%
26.44%
22.61%
25.15%
23.61%
Other Income
54.00
40.90
32.03%
43.20
24.70
74.90%
47.40
19.70
140.61%
38.40
24.60
56.10%
Interest
16.10
5.70
182.46%
5.00
1.40
257.14%
8.80
1.50
486.67%
6.50
2.93
121.84%
Depreciation
98.80
66.10
49.47%
72.50
62.80
15.45%
70.30
62.10
13.20%
68.30
59.61
14.58%
PBT
131.20
232.20
-43.50%
153.20
442.00
-65.34%
244.40
145.20
68.32%
203.60
466.72
-56.38%
Tax
37.60
55.20
-31.88%
10.30
58.20
-82.30%
54.40
24.10
125.73%
41.70
137.69
-69.71%
PAT
93.60
177.00
-47.12%
142.90
383.80
-62.77%
190.00
121.10
56.90%
161.90
329.03
-50.79%
PATM
10.02%
18.02%
15.35%
39.21%
18.19%
14.48%
16.97%
39.30%
EPS
1.36
2.78
-51.08%
2.13
6.01
-64.56%
2.86
1.72
66.28%
2.44
5.10
-52.16%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
1,608.67
1,053.79
Net Sales Growth
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
-23.73%
47.19%
52.66%
 
Cost Of Goods Sold
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
838.42
434.62
Gross Profit
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
770.25
619.17
GP Margin
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
47.88%
58.76%
Total Expenditure
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
1,285.31
757.67
Power & Fuel Cost
156.40
184.70
176.70
162.40
142.60
97.20
82.00
67.63
69.33
76.56
% Of Sales
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
4.31%
7.27%
Employee Cost
747.00
610.10
533.40
466.30
389.40
307.60
238.80
242.76
179.18
110.68
% Of Sales
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
11.14%
10.50%
Manufacturing Exp.
376.20
320.90
81.20
62.90
95.20
113.20
81.60
68.63
66.01
47.71
% Of Sales
9.67%
9.59%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
4.10%
4.53%
General & Admin Exp.
21.70
42.60
165.70
131.80
122.20
93.20
82.40
79.09
56.15
38.71
% Of Sales
0.56%
1.27%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
3.49%
3.67%
Selling & Distn. Exp.
107.40
100.80
108.70
118.90
99.60
89.40
62.40
56.49
47.67
32.53
% Of Sales
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
2.96%
3.09%
Miscellaneous Exp.
56.30
30.10
72.70
61.80
52.90
256.70
940.80
44.19
28.55
32.53
% Of Sales
1.45%
0.90%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
1.77%
1.60%
EBITDA
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
471.49
323.36
296.12
EBITDA Margin
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
20.10%
28.10%
Other Income
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
37.02
64.55
38.88
Interest
26.00
29.30
8.90
1.70
8.10
12.40
24.30
16.89
17.66
10.18
Depreciation
277.20
248.70
221.00
203.60
179.30
175.80
156.70
140.14
110.25
93.92
PBT
833.40
569.00
519.00
537.70
408.30
398.40
447.10
351.47
260.00
230.91
Tax
161.60
142.20
95.70
106.90
97.50
55.90
72.10
48.67
11.84
12.89
Tax Rate
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
10.50%
2.74%
PAT
595.80
528.70
497.40
413.80
508.90
341.60
367.50
293.25
93.84
463.91
PAT before Minority Interest
671.80
587.40
528.40
430.80
512.70
342.50
375.00
302.81
100.97
457.39
Minority Interest
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
-7.13
6.52
PAT Margin
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
5.83%
44.02%
PAT Growth
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
25.32%
212.50%
-79.77%
 
Unadjusted EPS
31.18
28.04
24.87
21.09
25.99
17.27
18.79
15.08
4.83
46.39

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
1,510.74
1,484.15
Share Capital
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
50.00
Total Reserves
4,737.70
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
1,369.32
1,397.80
Non-Current Liabilities
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
564.44
570.54
301.55
Secured Loans
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
331.50
395.73
135.04
Unsecured Loans
3.90
11.40
11.40
25.80
40.00
60.50
65.80
182.11
128.18
120.01
Long Term Provisions
36.00
29.90
15.00
7.80
4.00
0.00
1.00
0.00
0.00
0.00
Current Liabilities
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
438.50
301.42
Trade Payables
739.70
609.80
429.30
347.20
345.50
347.80
296.50
230.86
208.55
172.38
Other Current Liabilities
698.20
527.10
706.20
612.30
313.10
269.20
375.90
260.05
148.42
57.64
Short Term Borrowings
97.20
394.90
261.00
243.50
84.80
187.30
247.40
0.00
0.00
0.00
Short Term Provisions
143.20
133.90
158.20
176.60
246.50
211.50
140.80
90.83
81.53
71.40
Total Liabilities
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.80
Net Block
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
1,211.56
931.28
Gross Block
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
1,581.70
1,182.39
Accumulated Depreciation
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
499.20
370.14
251.11
Non Current Assets
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
1,422.68
1,101.10
Capital Work in Progress
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
172.02
138.21
Non Current Investment
188.80
26.80
0.00
64.50
64.50
64.20
60.90
47.16
39.10
31.60
Long Term Loans & Adv.
428.90
350.10
336.90
252.00
241.60
181.00
140.20
0.00
0.00
0.00
Other Non Current Assets
67.00
51.00
169.60
64.50
47.20
32.30
0.00
0.00
0.00
0.00
Current Assets
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
1,121.87
978.71
Current Investments
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
383.42
328.52
443.16
Inventories
635.30
542.40
452.70
376.60
398.40
378.30
413.70
371.64
319.18
178.98
Sundry Debtors
883.20
714.50
770.50
599.80
509.70
491.70
495.80
446.13
366.68
259.13
Cash & Bank
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
139.93
11.81
9.62
Other Current Assets
419.90
300.70
171.60
157.60
136.90
114.30
56.70
136.10
95.67
87.82
Short Term Loans & Adv.
267.80
227.10
75.80
81.80
81.40
37.10
20.20
120.28
95.05
82.76
Net Current Assets
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
683.37
677.28
Total Assets
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Cash From Operating Activity
526.40
210.70
560.70
471.20
564.10
798.50
443.81
95.10
317.91
154.76
PBT
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
104.36
538.66
211.00
Adjustment
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
135.89
-213.83
82.18
Changes in Working Capital
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
-128.21
17.34
-125.19
Cash after chg. in Working capital
773.20
344.10
709.40
565.20
638.00
879.80
476.60
112.04
342.18
167.99
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
-16.94
-24.27
-13.24
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
-232.19
-340.15
-191.17
Net Fixed Assets
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
-84.56
-53.65
-118.55
Net Investments
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
130.57
-430.24
92.04
Others
2,951.00
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
-278.20
143.74
-164.66
Cash from Financing Activity
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
136.93
23.22
43.09
Net Cash Inflow / Outflow
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
-0.16
0.99
6.68
Opening Cash & Equivalents
462.60
557.00
474.00
369.00
359.00
139.90
11.81
9.62
8.63
1.95
Closing Cash & Equivalent
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10
11.81
9.62
8.63

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
80.61
67.22
53.86
48.42
43.18
36.31
32.49
28.25
24.47
24.11
ROA
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
4.37%
25.03%
ROE
15.15%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
6.93%
36.76%
ROCE
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
6.92%
32.11%
Fixed Asset Turnover
0.89
1.05
1.09
1.12
1.11
1.06
0.97
1.42
1.19
0.96
Receivable days
74.35
80.16
80.09
69.48
72.22
84.37
93.20
60.98
69.27
95.54
Inventory Days
54.81
53.71
48.47
48.54
56.01
67.67
77.71
51.83
55.14
57.48
Payable days
79.07
68.27
58.15
55.73
65.24
70.25
70.62
41.52
51.80
83.01
Cash Conversion Cycle
50.09
65.60
70.42
62.29
62.99
81.79
100.29
71.30
72.61
70.02
Total Debt/Equity
0.48
0.61
0.35
0.30
0.10
0.12
0.17
0.30
0.36
0.18
Interest Cover
33.05
25.90
71.12
317.29
76.33
33.13
19.40
21.81
7.39
47.20

News Update


  • Biocon receives CRL from USFDA for proposed Biosimilar Pegfilgrastim
    10th Oct 2017, 09:06 AM

    The CRL relates to the pending update of the BLA with certain CMC data from facility requalification activities post recent plant modifications

    Read More
  • USFDA completes inspection at Biocon’s Vishakhapatnam facility
    18th Sep 2017, 16:01 PM

    The inspection was carried out between September 11, 2017 to September 15, 2017

    Read More
  • Biocon targeting $1 billion revenue by FY19
    11th Sep 2017, 12:00 PM

    The company is betting big on small molecules and generic formulations, biosimilars, branded formulations and research services

    Read More
  • Biocon’s arm receives EU GMP Compliance Certificate for insulin facility in Malaysia
    8th Sep 2017, 09:00 AM

    Biocon’s Malaysia facility was inspected by the EMA in April 2017

    Read More
  • Biocon, JDRF ink pact to support global multiple ascending dose study
    6th Sep 2017, 11:05 AM

    This collaboration with Biocon is a part of JDRF’s Industry Discovery and Development Partnership program

    Read More
  • Biocon to transfer Biosimilars business to step down subsidiary
    22nd Aug 2017, 13:48 PM

    The company has received approval to transfer the business by way of a slump sale as going concern to Biocon Biologics India

    Read More
  • Biocon gets 10 observations from USFDA for Benguluru plant: Report
    4th Aug 2017, 09:33 AM

    The US drug regulator found lapses of current good manufacturing practices at the company’s small molecule injectable plant in Bengaluru

    Read More
  • Biocon reports 51% fall in Q1 consolidated net profit
    28th Jul 2017, 12:02 PM

    Total consolidated income of the company increased by 4.38% at Rs 987.70 crore for quarter under review

    Read More
  • Biocon - Quarterly Results
    27th Jul 2017, 12:00 AM

    Read More
  • USFDA advisory committee approves Mylan, Biocon’s proposed biosimilar Trastuzumab
    14th Jul 2017, 08:50 AM

    The committee voted 16-0 in support of eligible indications of the reference product, Herceptin

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.